• 1
    Weber R, Sabin CA, Friis-Moller N et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 16321641.
  • 2
    Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013; 57: 249257.
  • 3
    Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012; 61 (Suppl 1): i47i58.
  • 4
    Cooper CL. Therapies for HIV and viral hepatitis coinfection. Expert Rev Anti Infect Ther 2005; 3: 8189.
  • 5
    Dornadula G, Zhang H, VanUitert B et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 1999; 282: 16271632.
  • 6
    Di Mascio M, Markowitz M, Louie M et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol 2003; 77: 1216512172.
  • 7
    Greub G, Cozzi-Lepri A, Ledergerber B et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16: 19671969.
  • 8
    Mira JA, Macias J, Nogales C et al. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir Ther 2002; 7: 251256.
  • 9
    Sklar PA, Ward DJ, Baker RK et al. Prevalence and clinical correlates of HIV viremia (‘blips’) in patients with previous suppression below the limits of quantification. AIDS 2002; 16: 20352041.
  • 10
    Lima V, Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009; 51: 36.
  • 11
    Nettles RE, Kieffer TL. Update on HIV-1 viral load blips. Curr Opin HIV AIDS 2006; 1: 157161.
  • 12
    Nettles RE, Kieffer TL, Kwon P et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005; 293: 817829.
  • 13
    Smit E, Bhattacharya S, Osman H, Taylor S. Increased frequency of HIV-1 viral load blip rate observed after switching from Roche Cobas Amplicor to Cobas Taqman assay. J Acquir Immune Defic Syndr 2009; 51: 364365.
  • 14
    Stosor V, Palella FJ Jr, Berzins B et al. Transient viremia in HIV-infected patients and use of plasma preparation tubes. Clin Infect Dis 2005; 41: 16711674.
  • 15
    Grennan JT, Loutfy MR, Su D et al. Magnitude of virologic blips is associated with a higher risk for virologic rebound in HIV-infected individuals: a recurrent events analysis. J Infect Dis 2012; 205: 12301238.
  • 16
    Easterbrook PJ, Ives N, Waters A et al. The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml. AIDS 2002; 16: 15211527.
  • 17
    Martinez V, Marcelin AG, Morini JP et al. HIV-1 intermittent viraemia in patients treated by non-nucleoside reverse transcriptase inhibitor-based regimen. AIDS 2005; 19: 10651069.
  • 18
    Orrell C, Kaplan R, Wood R, Bekker LG. Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy. AIDS Res Treat 2011; 2011: 469127.
  • 19
    Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS 2011; 25: 967975.
  • 20
    Klein MB, Saeed S, Yang H et al. Cohort profile: the Canadian HIV-hepatitis C co-infection cohort study. Int J Epidemiol 2010; 39: 11621169.
  • 21
    Al-Mohri H, Cooper C, Murphy T, Klein MB. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 2005; 6: 375378.
  • 22
    Al-Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007; 44: 463469.
  • 23
    Di Mascio M, Ribeiro RM, Markowitz M, Ho DD, Perelson AS. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math Biosci 2004; 188: 4762.
  • 24
    Percus JK, Percus OE, Markowitz M, Ho DD, Di Mascio M, Perelson AS. The distribution of viral blips observed in HIV-1 infected patients treated with combination antiretroviral therapy. Bull Math Biol 2003; 65: 263277.
  • 25
    Lo Re V 3rd, Lim JK, Goetz MB et al. Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the Veterans Aging Cohort Study. Pharmacoepidemiol Drug Saf 2011; 20: 689699.
  • 26
    Carlin JB, Wolfe R, Coffey C, Patton GC. Analysis of binary outcomes in longitudinal studies using weighted estimating equations and discrete-time survival methods: prevalence and incidence of smoking in an adolescent cohort. Stat Med 1999; 18: 26552679.
  • 27
    Lundgren JD, Babiker A, El-Sadr W et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis 2008; 197: 11451155.
  • 28
    El-Sadr WM, Lundgren JD, Neaton JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 22832296.
  • 29
    Tedaldi E, Peters L, Neuhaus J et al. Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008; 47: 14681475.
  • 30
    Brau N, Salvatore M, Rios-Bedoya CF et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 4755.
  • 31
    Schiavini M, Angeli E, Mainini A et al. Fibrosis progression in paired liver biopsies from HIV/HCV co-infected patients. Hepat Mon 2011; 11: 525531.
  • 32
    Lopez-Dieguez M, Montes ML, Pascual-Pareja JF et al. The natural history of liver cirrhosis in HIV-hepatitis C virus-coinfected patients. AIDS 2011; 25: 899904.
  • 33
    Garcia-Gasco P, Maida I, Blanco F et al. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome. J Antimicrob Chemother 2008; 61: 699704.
  • 34
    Havlir DV, Bassett R, Levitan D et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA 2001; 286: 171179.
  • 35
    Masquelier B, Pereira E, Peytavin G et al. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol 2005; 33: 7578.
  • 36
    Moore AL, Youle M, Lipman M et al. Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure? AIDS 2002; 16: 615618.
  • 37
    Podsadecki TJ, Vrijens BC, Tousset EP, Rode RA, Hanna GJ. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis 2007; 196: 17731778.
  • 38
    Raboud JM, Rae S, Woods R, Harris M, Montaner JS. Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients. AIDS 2002; 16: 16271632.
  • 39
    Sungkanuparph S, Overton ET, Seyfried W, Groger RK, Fraser VJ, Powderly WG. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis 2005; 41: 13261332.
  • 40
    Cooper CL. HIV antiretroviral medications and hepatotoxicity. Curr Opin HIV AIDS 2007; 2: 466473.
  • 41
    Leroy V, Vigan I, Mosnier JF et al. Phenotypic and functional characterization of intrahepatic T lymphocytes during chronic hepatitis C. Hepatology 2003; 38: 829841.
  • 42
    Glassner A, Eisenhardt M, Kokordelis P et al. Impaired CD4(+) T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J Hepatol 2013; 59: 427433.
  • 43
    Renton KW. Alteration of drug biotransformation and elimination during infection and inflammation. Pharmacol Ther 2001; 92: 147163.
  • 44
    Morgan ET, Li-Masters T, Cheng PY. Mechanisms of cytochrome P450 regulation by inflammatory mediators. Toxicology 2002; 181–182: 207210.
  • 45
    Reus S, Portilla J, Sanchez-Paya J et al. Low-level HIV viremia is associated with microbial translocation and inflammation. J Acquir Immune Defic Syndr 2013; 62: 129134.
  • 46
    Cales P, Halfon P, Batisse D et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol 2010; 53: 238244.
  • 47
    Loko MA, Castera L, Dabis F et al. Validation and comparison of simple noninvasive indexes for predicting liver fibrosis in HIV-HCV-coinfected patients: ANRS CO3 Aquitaine cohort. Am J Gastroenterol 2008; 103: 19731980.
    Direct Link:
  • 48
    Moodie EE, Pant Pai N, Klein MB. Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV/hepatitis C co-infected cohorts. PLoS ONE 2009; 4: e4517.